A Multi-Omics Study of Individual Responses to Long-**Term Mediterranean Diet Interventions in the DIRECT-PLUS** Trial

Danyue Dong¹, Meir J. Stampfer^{1,2,3}, Iris Shai^{2,5}, Curtis Huttenhower^{4,6,7}, Dong D Wang^{1,2,7}

¹ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA Departments of ²Nutrition, ³Epidemiology, ⁴Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA ⁵ Faculty of Health Sciences, The Health & Nutrition Innovative International Research Center, Ben-Gurion University of the Negev, Be'er Sheva, Israel ⁶ Harvard Chan Microbiome in Public Health Center, Harvard T.H. Chan School of Public Health, Boston, MA ⁷ Broad Institute of MIT and Harvard, Cambridge, MA;

Brigham and Women's Hospital Founding Member, Mass General Brigham

ABSTRACT

The benefits of the Mediterranean diet (MedDiet) for reducing metabolic risk vary significantly by individuals' gut microbial profiles. However, few studies have applied multi-omics to elucidate the personalized response and MedDiet's impact on the gut microbiome within a long-term randomized controlled trial. Here, we conducted a multiomics study, combining host genetics, metagenomics, and fecal and plasma metabolomics, in the DIRECT-PLUS trial of MedDiet Interventions. We revealed that baseline 'omic profiles explain substantial proportions of variation in individuals' response, quantified as changes in body adiposity and plasma biomarkers of metabolic risk and inflammation, following dietary interventions. A random forest model that integrates multi-omics exhibits exceptional performance in distinguishing those who respond to MedDiet from non-responders. Our study lays the groundwork for precision nutrition and discovered novel biological mechanisms for more effective prevention of metabolic disease.

Establishment of a Multi-Omics Study in a Successful Randomized Controlled MedDiet Trial



Fecal and Plasma Metabolomics: UPLC-MS/MS; Longitudinal sampling at baseline, 6 months, 18 months

BROAD INSTITUTE



RESULTS

Overview of metagenomic, fecal and plasma metabolomic data



- Plant polysaccharide degraders and butyrate producers are among the highly abundant gut microbes
- Most highly abundant fecal (5/10) or plasma (7/10) metabolites are xenobiotics
- Body mass index is significantly associated with overall plasma metabolome but not associated with gut microbiome and fecal metabolome

Substantial variability in individuals' responses to dietary interventions across multiple metabolic markers



CONCLUSIONS

- Our study highlights substantial inter-individual variations in response to long-term diet interventions, with multi-omics, particularly metagenomics and metabolomics, offering insights on explaining personalized responsiveness.
- Our study lays the groundwork for precision nutrition for more effective prevention of metabolic disease.

ACKNOWLEDGEMENT

This research was funded by the National Institutes of Health: R01NR01999, R00DK119412, and P30DK046200 DIRECT- PLUS trial was funded by the Deutsche Forschungsgemeinschaft (209933838), the Israel Ministry of Health (87472511), and the Israel Ministry of Science and Technology (3-13604) We sincerely thank all participants and staff of DIRECTPLUS for their great contributions to this research.

Foods from FFC Fecal Metabolites Plasma Metabolites

Food from FFQ Fecal Metabolite Plasma Metabolites

baseline data to predict responders vs. non-responders



Host genetics and baseline profiles of the gut microbiome, fecal and plasma metabolomes explained a substantial proportion of the personalized response to diet.



ACM: Anthropometric & Clinical Measures (Weight, BMI, WC, Pulse, DBP, SBP) Baseline fecal metabolites demonstrate the best performance in explaining individual responses to diet in glucose homeostasis, while the gut microbiome exhibits the best performance in explaining primary outcomes (adiposity)

Integration of multi-omics significantly improves the prediction of personalized responsiveness to diet

types in the final integrated model (7), with plasma metabolites contributing the most to the prediction

